Accessible pricing
It is not human safety information, not a usage guide for non-research settings, and not medical, clinical, veterinary, cosmetic, dietary, or personal-use guidance
Oral is unproven and likely less effective
The general math works as follows: Example A: 5,000 mcg vial + 2 mL bacteriostatic water: Yields 2,500 mcg per mL
Angiogenic Pathway Activation Multi-Component Blood Vessel Formation Multiple components contribute to comprehensive angiogenesis through distinct but complementary mechanisms[5]: BPC-157 upregulates VEGFR2 expression and enhances endothelial cell proliferation TB-500 promotes endothelial cell migration and tube formation GHK-Cu stimulates angiogenic growth factor expression and vessel maturation Combined effects result in robust tissue vascularization and nutrient delivery Improved collateral circulation development in ischemic conditions Nitric Oxide System Modulation Vascular Protection BPC-157 influences nitric oxide signaling pathways to support vascular function[6]: Enhanced eNOS phosphorylation leading to controlled NO production Modulation of blood flow and vascular tone Protection against both NO excess and NO deficiency states Coordination with angiogenic effects for comprehensive vascular support Synergistic Advantage: KLOW Blends four-pathway approach enables simultaneous activation of cellular migration (BPC-157/TB-500), matrix synthesis and gene expression modulation (GHK-Cu), robust inflammation control (KPV), and comprehensive angiogenesis
Yes (strong) FDA status FDA-approved (T2D and obesity) Compound NAD+ (intravenous or subcutaneous) Mechanism Direct NAD+ supplementation Route IV infusion or subcutaneous Acts on appetite
